Tacrolimus pharmacokinetics

Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John s Wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004 44(l) 89-94. [Pg.102]

Bekersky I, Dressier D, Alak A, et al. (2001) Comparative tacrolimus pharmacokinetics normal versus mildly hepatically impaired subjects. / Clin Pharmacol 41 628-635. [Pg.133]

Tada H, Yanagiwara S, Ito K, Suzuki T. Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. Pharmacol Toxicol 1999 84 241 -246. [Pg.678]

Dansirikul C, Staatz CE, DufTull SB, Taylor PJ, Lynch SV, Tett SE. Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients. JC/iwP/ianw Ther (2006) 31, 17-25. [Pg.1043]

The effects of methylprednisiolone on tacrolimus pharmacokinetics are uncertain. Prednisone appears to reduce the levels of tacrolimus. [Pg.1078]

Caspofungin moderately decreases tacrolimus levels. Anidulafun-gin and micafungin do not appear to affect tacrolimus pharmacokinetics, and tacrolimus does not affect the pharmacokinetics of aniduiafungin, caspofungin, or micafungin. [Pg.1078]

Hebert MF, Fisher RM, Marsh CL, Dressier D, Bekersl I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. JC/mP/iorwaco/(1999) 39, 91-6. [Pg.1083]

Baldan N, Rigotti P, Furian L, Margani G, Ekser B, Frison L, De Martin S, Palatini P. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients Pharmacol Res (2006) 54,181-5. [Pg.1084]

Ali SM, Ahmad A, Sheikh S, Ahmad MU, Rane RC, Kale P, Paithankar M, Saptarishi D, Sehgal A, Maheshwari K, Ahmad I. Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant tacrolimus pharmacokinetics, safety, and tolerability in rodents and humans. Lit Lmnunophaima-col 2010 10(3) 325-30. [Pg.648]

Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, Midtvedt K. Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. Transplantation 2009 87(8) 1221-4. [Pg.24]

Rimonabant The pharmacokinetic interaction of ciclosporin with rimonabant has been studied in 10 stable renal transplant recipients [24 ]. Rimonabant caused a moderate but significant increase in ciclosporin AUCo i2h) with non-significant rises in Cmax and C2 concentrations. Tacrolimus pharmacokinetics were not significantly affected by rimonabant in eight patients. [Pg.817]

Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int April 2012 25(4) 471-80. PubMed PMID 22369694. Epub 2012/03/01. eng. [Pg.601]

Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene January 10, 2013 512(2) 226-31. PubMed PMID 23107770. Epub 2012/10/31. eng. [Pg.601]

Cyclosporine, tacrolimus, and sirolimus are all metabolized via the CYP3A4 pathway therefore, it would be anticipated that they would experience similar pharmacokinetic DDIs. Table 52-6 details some clinically relevant DDIs that occur... [Pg.843]

Most pharmacokinetic interactions in transplantation occur due to interactions with the CYP enzyme system however, several interactions have been shown to occur via alternative mechanisms. One of the most notable is that seen between tacrolimus and some of the prokinetic agents. Cisapride and metoclopramide have been shown to increase the absorption of tacrolimus by enhancing gastric emptying.41... [Pg.843]

Budde K, Glander P, Grohmann J, Bauer S, Hambach P, Hepburn H, Mai I, Sandau K, Fischer W, Neumayer HH. (2004) Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) in maintenance renal transplant patients with tacrolimus as basic immunosuppression (P736). Transplantation 78 459 60. [Pg.160]

Pharmacology Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. The mechanism of action of tacrolimus in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. Pharmacokinetics ... [Pg.2067]

Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St John s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003 18(4) 819-822. [Pg.103]

Christians U, Jacohsen W, Benet LZ, et al. Mechanisms of clinically relevant dmg interactions associated with tacrolimus. Clin Pharmacokinet 2002 41 813-851. [Pg.700]

While tacrolimus had no effect on the plasma pharmacokinetics of caspofungin, chronic caspofungin reduced the AUC of tacrolimus by about 20% (5). [Pg.1200]

Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998 46(3) 271-2. [Pg.1388]

In a non-randomized, pharmacokinetic study, four patients taking tacrolimus after kidney and liver... [Pg.3287]

An increase in tacrolimus trough blood concentrations has been attributed to concomitant theophylline therapy in a 33-year-old man with a renal transplant (122). A subsequent pharmacokinetic study showed that theophylline increased the AUC of oral tacrolimus six-fold. [Pg.3288]

Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002 41(5) 381-8. [Pg.3291]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...